BIO

Lindsay Pratt, PA-C, is a physician assistant with 15 years of experience in hepatology and liver transplantation. She currently practices at the University of Colorado in the Department of Hepatology and Liver Transplantation, where she dedicates the majority of her time to patient care. In addition to her clinical role, she serves as an assistant professor in the School of Medicine, actively contributing to education through lectures for the PA program and precepting PA students in the clinic.

Lindsay manages a wide range of liver diseases, including MASLD/MASH, hepatitis B and C, autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Wilson's disease, and hemochromatosis. She also cares for patients with compensated and decompensated cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma, including those awaiting liver transplant.

She has a particular passion for MASLD/MASH and holds an advanced certificate in obesity medicine, which enhances her ability to support this patient population. Lindsay also has a personal and professional interest in PBC, inspired by her experience as a live liver donor for her mother nearly 20 years ago.

For Lindsay, the most rewarding aspects of her work are educating patients and collaborating with her fellow advanced practice providers. She looks forward to being an active member of this community network, supporting patient education and partnering with other providers to improve care for the growing MASLD/MASH population.

MASLD-MASH Content Featuring Lindsay

Related Content

Serological Workup: A Step-by-Step Guide

July 2025

In this comprehensive video, Sherona Bau, NP from UCLA, breaks down the essential hepatology workup for patients with MASLD (formerly NAFLD) and MASH, offering guidance for both primary care providers and GI/hepatology specialists. Drawing from her extensive clinical experience, she outlines a systematic approach to evaluating abnormal liver ultrasound findings—starting with critical labs to rule out chronic liver conditions like hepatitis B, hepatitis C, autoimmune hepatitis, PBC, and hereditary hemochromatosis. Sherona discusses the importance of ordering ANA, AMA, ferritin, serologies, and even specialized labs like the phosphatidylethanol (PEth) test to uncover alcohol-related liver disease that may be overlooked. She emphasizes the need to screen for cardiometabolic risk factors including type 2 diabetes and dyslipidemia and highlights non-invasive tests such as FibroScan and FIB-4 to help identify patients at risk of advanced fibrosis who may benefit from specialist referral. Most importantly, Sherona addresses the fears many patients face around liver disease progression and life expectancy, encouraging early intervention and coordinated care to improve long-term outcomes. This video is a must-watch for any clinician managing steatotic liver disease.

Watch Now arrow

MASH/MASLD in Type 2 Diabetes: Concurrent Medication Management

July 2025

In this informative episode, Whitney Steinmetz, NP from Presbyterian Medical Group in Albuquerque, NM, explores how to optimize medication strategies for patients with type 2 diabetes who are also living with MASLD and MASH. She discusses why individuals with type 2 diabetes are at significantly higher risk for developing advanced liver fibrosis—highlighting the overlapping metabolic, inflammatory, and insulin-resistant pathways that accelerate liver damage. Whitney breaks down how commonly prescribed diabetes medications—like GLP-1 receptor agonists, SGLT2 inhibitors, TZDs, and dual/triple incretins—impact liver fat, inflammation, and fibrosis progression. She offers practical guidance on selecting therapies that balance glycemic control with hepatic benefits while minimizing polypharmacy. Learn which medications may offer dual cardiometabolic and hepatic advantages, and which should be avoided or used with caution in patients with cirrhosis or advanced fibrosis. Tune in for real-world insights into how advanced practice providers can take ownership of MASH management in diabetes care.

Watch Now arrow